SEARCH

SEARCH BY CITATION

References

  • 1
    Bilezikian JP. Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med. 2006; 355: 227881.
  • 2
    Hellstein JW, Marek CL. Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg. 2004; 62: 15635.
  • 3
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61: 11157.
  • 4
    Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 156775.
  • 5
    Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144: 75361.
  • 6
    Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer. 2011; 19: 203540.
  • 7
    Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 81322.
  • 8
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 51329.
  • 9
    Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von MR, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29: 112532.
  • 10
    Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003; 5: 6574.
  • 11
    Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97: 26926.
  • 12
    Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011; 48: 969.
  • 13
    Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011; 48: 67792.
  • 14
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 82131.
  • 15
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 147991.
  • 16
    Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009; 35: 11930.
  • 17
    Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006; 7: 50814.
  • 18
    Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104: 8393.
  • 19
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62: 52734.
  • 20
    Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007; 18: 136370.
  • 21
    Gupta O, Shaw J. The relation of a chelating agent to smooth-surface lesions in the white rat. J Nutr. 1956; 60: 31122.
  • 22
    Gupta O, Shaw J. Periodontal disease in the rice rat. II. Methods for the evaluation of the extent of periodontal disease. Oral Surg Oral Med Oral Pathol. 1956; 9: 72735.
  • 23
    Gupta O, Shaw J. Periodontal disease in the rice rat. I. Anatomic and histopathologic findings. Oral Surg Oral Med Oral Pathol. 1956; 9: 592603.
  • 24
    Ryder MI. Histological and ultrastructural characteristics of the periodontal syndrome in the rice rat. I. General light microscopic observations and ultrastructural observations of initial inflammatory changes. J Periodontal Res. 1980; 15: 50215.
  • 25
    Aguirre JI, Akhter M, Kimmel D, Pingel J, Xia X, Williams A, Jorgensen M, Edmonds K, Lee J, Reinhard M, Battles A, Kesavalu L, Wronski TJ. Enhanced alveolar bone loss in a model of non-invasive periodontitis in rice rats. Oral Dis. Epub 2011 Jan 11. DOI: 10.1111/j.1601-0825.2011.01893.x.
  • 26
    Auskaps A, Gupta O, Shaw J. Periodontal disease in the rice rat. III. Survey of dietary influences. J Nutr. 1957; 63: 32543.
  • 27
    Gotcher JE, Jee WS. The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies. J Periodontal Res. 1981; 16: 27591.
  • 28
    Hattler AB, Snyder DE, Listgarten MA, Kemp W. The lack of pulpal pathosis in rice rats with the periodontal syndrome. Oral Surg Oral Med Oral Pathol. 1977; 44: 93948.
  • 29
    Leonard EP. Periodontitis. Animal model: periodontitis in the rice rat (Oryzomys palustris). Am J Pathol. 1979; 96: 6436.
  • 30
    Gotcher JE, Jee WS. The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium. J Periodontal Res. 1981; 16: 44155.
  • 31
    Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone. 2007; 41: 2906.
  • 32
    Aguirre JI, Altman MK, Vanegas SM, Franz SE, Bassit AC, Wronski TJ. Effects of alendronate on bone healing after tooth extraction in rats. Oral Dis. 2010; 16: 67485.
  • 33
    Verma RK, Rajapakse S, Meka A, Hamrick C, Pola S, Bhattacharyya I, Nair M, Wallet SM, Aukhil I, Kesavalu L. Porphyromonas gingivalis and Treponema denticola mixed microbial infection in a rat model of periodontal disease. Interdiscip Perspect Infect Dis. 2010; 2010: 60512531.
  • 34
    Verma RK, Bhattacharyya I, Sevilla A, Lieberman I, Pola S, Nair M, Wallet SM, Aukhil I, Kesavalu L. Virulence of major periodontal pathogens and lack of humoral immune protection in a rat model of periodontal disease. Oral Dis. 2010; 16: 68695.
  • 35
    Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res. 2007; 22: 175965.
  • 36
    Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact. 2007; 7: 35860.
  • 37
    Burr DB, Hooser M. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone. 1995; 17: 4313.
  • 38
    Frost HM. Bone histomorphometry: analysis of trabecular bone dynamics. In: Recker RR, editor. Bone histomorphometry: techniques and interpretation. 1st ed. Boca Raton, FL: CRC Press; 1983. p. 10932.
  • 39
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595610.
  • 40
    Bainbridge B, Verma RK, Eastman C, Yehia B, Rivera M, Moffatt C, Bhattacharyya I, Lamont RJ, Kesavalu L. Role of Porphyromonas gingivalis phosphoserine phosphatase enzyme SerB in inflammation, immune response, and induction of alveolar bone resorption in rats. Infect Immun. 2010; 78: 45609.
  • 41
    Noble BS, Stevens HY. Techniques for the study of apoptosis in bone. Methods Mol Med. 2003; 80: 22536.
  • 42
    Mann V, Huber C, Kogianni G, Jones D, Noble B. The influence of mechanical stimulation on osteocyte apoptosis and bone viability in human trabecular bone. J Musculoskelet Neuronal Interact. 2006; 6: 40817.
  • 43
    Jiang X, Kalajzic Z, Maye P, Braut A, Bellizzi J, Mina M, Rowe DW. Histological analysis of GFP expression in murine bone. J Histochem Cytochem. 2005; 53: 593602.
  • 44
    Park C, Abramson Z, Taba MJ, Jin Q, Kreider J, Goldstein S, Giannobile WV. Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol. 2007; 78: 27381.
  • 45
    Liu XM, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA, Wang D. Osteotropic beta-cyclodextrin for local bone regeneration. Biomaterials. 2008; 29: 168692.
  • 46
    Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res. 2001; 16: 76573.
  • 47
    Aguirre JI, Altman MK, Franz SE, Bassit ACF, Wronski TJ. Alendronate transiently impairs removal of alveolar bone and healing of the root socket after tooth extraction in rats. J Bone Miner Res. 2008; 23: S76.
  • 48
    Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, Bezouglaia O, Dry SM, Tetradis S. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res. 2011; 26: 187182.
  • 49
    Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23: 82636.
  • 50
    Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009; 45: 40613.
  • 51
    Hutchinson M, O'Ryan F, Chavez V, Lathon PV, Sanchez G, Hatcher DC, Indresano AT, Lo JC. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010; 68: 223240.
  • 52
    Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011 Nov 29; 8(2): 906.
  • 53
    Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011; 1218: 3846.
  • 54
    Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis. 2009; 15: 8892.
  • 55
    Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol. 2011; 7: 3442.
  • 56
    Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo RL, Lo ML, Nocini PF. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105: 35864.
  • 57
    Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr. 2006; 118: 4738.
  • 58
    Maahs MP, Azambuja AA, Campos MM, Salum FG, Cherubini K. Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. Head Neck. 2011; 33: 199207.
  • 59
    Pautke C, Otto S, Reu S, Kolk A, Ehrenfeld M, Sturzenbaum S, Wolff KD. Bisphosphonate related osteonecrosis of the jaw—manifestation in a microvascular iliac bone flap. Oral Oncol. 2011; 47: 4259.
  • 60
    Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009; 44: 410.
  • 61
    Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005; 63: 6829.
  • 62
    Hansen T, Kunkel M, Weber A, James KC. Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006; 35: 15560.
  • 63
    Belibasakis GN, Meier A, Guggenheim B, Bostanci N. Oral biofilm challenge regulates the RANKL-OPG system in periodontal ligament and dental pulp cells. Microb Pathog. 2011; 50: 611.
  • 64
    Belibasakis GN, Bostanci N, Hashim A, Johansson A, Aduse-Opoku J, Curtis MA, Hughes FJ. Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. Microb Pathog. 2007; 43: 4653.
  • 65
    Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 1996; 64: 237180.
  • 66
    Ohnuki H, Izumi K, Terada M, Saito T, Kato H, Suzuki A, Kawano Y, Nozawa-Inoue K, Takagi R, Maeda T. Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes. Arch Oral Biol. Epub 2011 Dec 13. DOI: 10.1016/j.archoralbio.2011.11.015.
  • 67
    Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009; 144: 66776.
  • 68
    Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62: 653844.
  • 69
    Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003; 9: 28937.
  • 70
    Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, Yatani H, Yoneda T. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2010; 28: 16575.